Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02872597 · ClinicalTrials.gov registry record · Phase 1
Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus
A Phase 1 study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02872597 is a Phase 1 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT02872597, a Phase 1 study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is a Phase I study to investigate the addition of inhaled Ipratropium bromide to standard therapy in the treatment of severe asthma attacks in children admitted to the Pediatric Intensive Care Unit. Half of the subjects will receive inhaled Ipratropium, and half will receive an inhaled placebo.
Interventions
- DRUG Albuterol
- DRUG 0.9% Sodium Chloride
- DRUG corticosteroids
- DRUG Ipratropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-09-05 |
| Est. Completion | 2018-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02872597
The ClinicalTrials.gov registry entry for NCT02872597 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Albuterol is the first listed.
NCT02872597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02872597 about?
NCT02872597 is a clinical study titled "Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus". This study is a Phase I study to investigate the addition of inhaled Ipratropium bromide to standard therapy in the treatment of severe asthma attacks in children admitted to the Pediatric Intensive Care Unit. Half of the subjects will receive inhaled Ipratropium, and half will receive an inhaled pl...
What is the current status of trial NCT02872597?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-09-05. Estimated completion is 2018-08-16.
What interventions are being tested in trial NCT02872597?
The interventions under investigation include: Albuterol (DRUG), 0.9% Sodium Chloride (DRUG), corticosteroids (DRUG), Ipratropium (DRUG).
Who is sponsoring clinical trial NCT02872597?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.